While in town, Nigel also stopped to see an old friend, Pablo Magnani, at Moehs. The company has just built a beautiful new lab in the heart of Barcelona.
While in town, Nigel also stopped to see an old friend, Pablo Magnani, at Moehs. The company has just built a beautiful new lab in the heart of Barcelona.
Nigel took a quick trip over to Barcelona to see the CEO of Uquifa, only to be greeted by heavy rain.
Behind the scenes at the BEAM part at this year’s AMR Conference in Basel.
Mark Bamforth, Dr. Richard Snyder, and Nigel Walker are making valuable connections at the AMR Conference in Basel, Switzerland, where they are sharing more about disAMR, a newly launched hub for AMR communications, education, and advocacy.
Armed with a fresh set of business cards, the disAMR team is headed to Basel, Switzerland, today to attend the AMR Conference.
It’s not every day you get to partner with a genius scientist and a self-made billionaire. Mark Bamforth OBE, Dr. Richard Snyder, and Nigel Walker founded disAMR to combat the ever-challenging topic of Anti-Microbial Resistance. This new platform is the first operating role Nigel has taken on since starting That’s Nice more than 30 years ago.
disAMR has acquired AMR Insights and will look to build upon the foundation Maarten developed eight years ago.
We’re pleased to announce the launch of disAMR (formerly AMR Insights). disAMR, pronounced “disarm” as it is committed to combating the threat of AMR, will serve as a nexus for AMR communications, education, and advocacy—connecting stakeholders, promoting innovation, shaping policy, and supporting sustainable antimicrobial product development. Learn more at www.disamr.com.
Another shot of Prof. Dan Smith’s presentation at ATW 2026. Did you know that most of the info in this presentation was sourced directly from Nice Insight’s 2026 State of the Industry Report? The open-access report is available for download right now on www.PharmasAlmanac.com.
At Advanced Therapies Week in San Diego, we were honored to secure a speaking slot, where our CSO, Dan, presented on key trends shaping the advanced therapies CDMO landscape.